Skip to main content

Table 3 Examples of drug repositioning applications in various disease areas and related therapeutics

From: A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions

Disease area Drug name/active ingredients Original indication New indication(s) New indication(s) status
Depression Duloxetine hydrochloride Major Depressive Disorder (MDD) Neuropathic pain, generalized anxiety disorder (GAD), osteoarthritis, and stress incontinence Approved
Fluoxetine hydrochloride Major Depressive Disorder (MDD) Premenstrual dysphoric disorder (PMDD) Approved
Sibutramine hydrochloride Major Depressive Disorder (MDD) Obesity Approved
Neurology Atomoxetine hydrochloride Parkinson’s disease (PD) Attention-deficit hyperactivity disorder (ADHD) Approved
Ropinirole hydrochloride Hypertension (HTN) Parkinson’s disease (PD) Approved
Non-neurology Minoxidil Hypertension (HTN) Hair loss Approved
Finasteride Benign prostatic hyperplasia (BPH) Hair loss Approved
Zidovudine Failed clinical trials for cancer Human immunodeficiency virus (HIV) Approved
Sildenafil Angina Erectile dysfunction (ED) and pulmonary arterial hypertension (PAH) Approved
Cancer Auranofin Rheumatoid arthritis (RA) Gastrointestinal stromal tumor (GIST) Approved
Imatinib Chronic myeloid leukemia (CML) Gastrointestinal stromal tumors (GIST) Approved
Irinotecan hydrochloride Colorectal cancer Pancreatic cancer Approved
Nelfinavir Human immunodeficiency virus 1 (HIV-1) Colorectal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, metastatic cancer Investigational
  Metformin hydrochloride Type 2 diabetes (T2DM) Breast cancer, pancreatic cancer, endometrial cancer, colorectal cancer, and esophageal cancer Investigational
Trastuzumab Human epidermal growth factor receptor 2 (HER2)-positive breast cancer Metastatic breast cancer, gastric cancer, and early breast cancer Approved
Sunitinib Renal cell carcinoma (RCC) and Gastrointestinal stromal tumor (GIST) Pancreatic neuroendocrine tumors (PNETs) Approved
Crizotinib Clinical trials for anaplastic large cell lymphoma (ALCL) Non-small cell lung cancer (NSCLC) Approved
Infectious Thalidomide Morning sickness (withdrawn) Erythema nodosum leprosum (Leprosy) Approved
Everolimus Immunosuppressant Pancreatic neuroendocrine tumors (PNETs), renal cell carcinoma (RCC), and subependymal giant cell astrocytoma (SEGA) Approved
Sirolimus Organ rejection in patients receiving renal transplants Malaria Investigational
Rare and orphan Alefacept Chronic plaque psoriasis Rejection in patients receiving allogeneic solid organ transplants Investigational
Indium In-111 pentetreotide Agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors Neuroendocrine tumors (NETs) Investigational